Cross platform analysis of drug targets and toxicity of bath salts

药物靶点和浴盐毒性的跨平台分析

基本信息

项目摘要

Project Summary/Abstract The United States is in the midst of a substance abuse and mental health epidemic. Over the past decade, abuse of psychostimulant (and sometimes hallucinogenic) cathinones, often referred to as “bath salts”, and variants such as ‘flakka’, has become increasing popular in America’s youth. Although there has been substantial research into the mechanisms underlying the addictive and adverse effects of some of these agents, such as 3,4-methylenedioxymethamphetamine (MDMA), a wide variety of variants are available for sale on the internet. Furthermore, these represent only a small fraction of conceivable structures which can be produced on kilograms scale for sale online. Gaining a more complete understanding of the drug targets and toxicity associated with these agents is an important step to treat substance abuse disorders and episodic toxicity. The over-arching goal of our work is to unite whole system level analysis involving the neurobehavioral effects of psychoactive agents with the study of binding partners at the molecular level. The focus of this proposal is to implement a novel in vivo photoaffinity labeling (PAL) approach for cross platform analysis of psychoactive agents, with an emphasis on structures related methylenedioxypyrovalerone (MDPV) and α- pyrrolidinovalerophenone (α-PVP). In Aim 1 we will synthesize a carefully designed set of probes to be cataloged in Aim 2 assays. This includes stereoselective synthesis of PAL probes, structure activity relationship (SAR) controls, and stable isotope labeled standards for LC-MS studies in Aim 2C. The synthesized library will be assayed for 1) receptor binding profile; 2) effect on monoamine uptake and release in rat synaptosomes; and 3) toxicity in multiple cell lines HepG2 (liver), SHSY-5Y (neuronal), AC16 (cardiac myocyte) and PC-12 (neuronal [rat]). In Aim 2C, active compounds (and select inactive controls) will be studied in an adult zebrafish behavioral paradigm utilizing the novel tank test with concurrent in vivo PAL. The concentration of each drug will be measured by LC-MS/MS to correlate target tissue (brain) drug exposure with behavioral responses. Select compounds will be re-examined in the Aim 2 assays using PAL for side-by-side comparison of binding interactome of Aim 2 experimental systems versus the in vivo binding interactome. Chemical biology in Aim 3 will utilize click chemistry to visualize protein labeling via fluoroimaging of SDS PAGE gels. Proteomics will determine protein identification after affinity purification to define the binding interactome of each probe. A variety of competition experiments will be performed to characterize background PAL and recognize bona fide targets. Bioinformatics will be used for network analysis to provide an unbiased comparison of the binding interactomes for each experimental system to propose potential therapeutic targets to treat toxicity and episodic lethality of these agents.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Isaac T Schiefer其他文献

Isaac T Schiefer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Isaac T Schiefer', 18)}}的其他基金

Cross platform analysis of drug targets and toxicity of bath salts
药物靶点和浴盐毒性的跨平台分析
  • 批准号:
    10704604
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease
开发减毒呋喃酮作为阿尔茨海默病的新疗法
  • 批准号:
    10337296
  • 财政年份:
    2018
  • 资助金额:
    $ 48.01万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 48.01万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 48.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 48.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 48.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 48.01万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了